Which is better, ANIP or GMAB?

On the Buffett-Fit framework, Genmab A/S (GMAB) currently grades higher than ANIP — 65/100 (C grade) vs 53/100 (C). That said, "better" depends on which framework you trust — ANIP wins on Philip Fisher and Peter Lynch; GMAB wins on Warren Buffett, Benjamin Graham, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy ANIP or GMAB?

This page is an educational comparison, not investment advice. Both ANIP and GMAB are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is ANIP better than GMAB for value investing?

On the Buffett-style value-investing framework, GMAB currently grades higher — 65/100 vs 53/100, a 12-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between ANIP and GMAB on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). ANIP currently scores 53/100 (C grade); GMAB scores 65/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, ANIP or GMAB?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. ANIP and GMAB are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, ANIP or GMAB?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are ANIP and GMAB both Healthcare stocks?

Yes — both ANI Pharmaceuticals, Inc. (ANIP) and Genmab A/S (GMAB) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this ANIP vs GMAB comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

ANI Pharmaceuticals

Genmab A/S

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

ANIP

ANI Pharmaceuticals

Market cap

$1.88B

Sector

Healthcare

GMAB

Genmab A/S

Market cap

$16.5B

Sector

Healthcare

Overall winner

Genmab A/S GMAB

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	ANIP	GMAB	Winner
Warren Buffett	53C	65C	GMAB
Benjamin Graham	59D	64C	GMAB
Philip Fisher	58C	48D	ANIP
Peter Lynch	71C	25F	ANIP
Joel Greenblatt	44D	76B	GMAB
Charlie Munger	47D	68C	GMAB
Terry Smith	50D	71C	GMAB

Side-by-side metrics

Metric	ANIP	GMAB
Market cap	$1.88B	$16.5B
P/E (TTM)	18.5x	6.2x
EV/EBIT	22.4x	12.0x
ROIC (TTM)	8.17%	43.78%
Gross margin	65.94%	93.88%
Net margin	9.71%	18.23%
Revenue CAGR 5y	42.18%	-18.45%
EPS CAGR 5y	-	-23.48%
Debt / Equity	0.6x	0.1x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ANIP leads on

Revenue CAGR 5y42.18%vs -18.45%+144%

GMAB leads on

Market cap$16.5Bvs $1.88B+89%
Debt / Equity0.1xvs 0.6x+87%
ROIC (TTM)43.78%vs 8.17%+81%
P/E (TTM)6.2xvs 18.5x+67%

More like ANIP

ANIP vs IDXX ANIP vs 7741.T ANIP vs LMAT ANIP vs HALO ANIP vs SUNPHARMA.NS ANIP vs MTD

More like GMAB

GMAB vs IDXX GMAB vs 7741.T GMAB vs LMAT GMAB vs HALO GMAB vs SUNPHARMA.NS GMAB vs MTD

Read the full Buffett-Brain analysis for ANIP Read the full Buffett-Brain analysis for GMAB

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

ANI Pharmaceuticals

Genmab A/S

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

ANIP

ANI Pharmaceuticals

Market cap

$1.88B

Sector

Healthcare

GMAB

Genmab A/S

Market cap

$16.5B

Sector

Healthcare

Overall winner

Genmab A/S GMAB

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	ANIP	GMAB	Winner
Warren Buffett	53C	65C	GMAB
Benjamin Graham	59D	64C	GMAB
Philip Fisher	58C	48D	ANIP
Peter Lynch	71C	25F	ANIP
Joel Greenblatt	44D	76B	GMAB
Charlie Munger	47D	68C	GMAB
Terry Smith	50D	71C	GMAB

Side-by-side metrics

Metric	ANIP	GMAB
Market cap	$1.88B	$16.5B
P/E (TTM)	18.5x	6.2x
EV/EBIT	22.4x	12.0x
ROIC (TTM)	8.17%	43.78%
Gross margin	65.94%	93.88%
Net margin	9.71%	18.23%
Revenue CAGR 5y	42.18%	-18.45%
EPS CAGR 5y	-	-23.48%
Debt / Equity	0.6x	0.1x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ANIP leads on

Revenue CAGR 5y42.18%vs -18.45%+144%

GMAB leads on

Market cap$16.5Bvs $1.88B+89%
Debt / Equity0.1xvs 0.6x+87%
ROIC (TTM)43.78%vs 8.17%+81%
P/E (TTM)6.2xvs 18.5x+67%

More like ANIP

ANIP vs IDXX ANIP vs 7741.T ANIP vs LMAT ANIP vs HALO ANIP vs SUNPHARMA.NS ANIP vs MTD

More like GMAB

GMAB vs IDXX GMAB vs 7741.T GMAB vs LMAT GMAB vs HALO GMAB vs SUNPHARMA.NS GMAB vs MTD

Read the full Buffett-Brain analysis for ANIP Read the full Buffett-Brain analysis for GMAB

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.